Antiarrhythmic drug therapy with verapamil/quinidine to restore sinus rhythm and prevent recurrences of paroxysmal or chronic atrial fibrillation or flutter;Konversionsrate und Rezidivprophylaxe bei paroxysmalem und anhaltendem Vorhofflimmern oder Vorhofflattern mit Verapamil/Chinidin

Medizinische Klinik

Volumn 91, Issue 10, 1996, Pages 617-625

  Trappe, Hans Joachim ^a,b   Pfitzner, Petra ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

QUINIDINE; VERAPAMIL;

ADULT; AGED; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CLINICAL FEATURE; DRUG EFFECT; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; LONG QT SYNDROME; MAJOR CLINICAL STUDY; MALE; RECURRENT DISEASE; SINUS RHYTHM; TREATMENT OUTCOME;

ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINIDINE; RETROSPECTIVE STUDIES; TACHYCARDIA, PAROXYSMAL; TREATMENT OUTCOME; VERAPAMIL;

EID: 0029851392     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Abbott, W. M., R. D. Maloney, C. C McCabe, C. E. Lee, L. S. Wirthlin: Arterial embolism: a 44 year perspective. Amer. J. Surg. 1243 (1982), 460-464.
2. Ahnve, S., Correction of the QT interval for heart rate: review of different formulas and the use of Bazett's formula in myocardial infarction. Amer. Heart J. 109 (1985), 568-574
3. Alpert, J. S.: Atrial fibrillation: natural history, complications and management. Ann. Rev. Med 39, (1988), 41-52.
4. Anderson, J., E Gilpert, B Alpert, R. Henthorn, A. Waldo, A. Bhandari, R. Hawkinson, E. Pritchett, the Flecainide supraventricular tachycardia study group Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. Circulation 80 (1989), 1557-1570.
5. Andresen, D , T. Brüggemann, C. Ehlers: Klinik und Prognose des Vorhofflimmerns. Z Kardiol. 83 (1994), 35-39.
6. Antman, E. M., A. D. Beamer, C. Cantillon: Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs. J. Amer. Coll. Cardiol. 15 (1990), 698-707.
7. Bachour, G : Antiarrhythmische Langxeittherapie mit Chimdin/Verapamil-Kombination. Herz Kreisl. 14 (1982), 33-41.
8. Beck, O. A., R. Günther, H. Hochrein: Kombinierte Anwendurig von Chinidin und Veraparnil bei chronischem Vorhofflimmern und -flattern. Münch, med. Wschr. 124 (1982), 383-386.
9. Belz, G., K. Olesch, J Schmidt-Voigr Díe Behandlung des chronischen Vorhofflimmerns mit einer Kombination von Chinidin und Verapamil Med. Welt (Stuttg.) 21 (1970), 1670-1672.
10. Benditt, D. G., S. Bailin, S Remole, S. Milstein: Proarrhythmia: recognition of patients at risk. J. cardiovasc. Electrophys 2 (1991), 221-232.
11. Boissel, J. P., E. Wolf, J. Gillet Controlled trial of a longacting quinidine for maintenance of sinus rhythm after convetsion of sustained atrinal fibrillation. Europ. Heart J. 2 (1981), 49-55.
12. Breithardt, G., H. Kottkamp, W. Haverkamp, G. Hindricks, T. Fetsch, M. Borggrefe, Probleme der aritiarrhythmischen Therapie bei Vorhofflimmern. Z. Kardiol. 83 (1994), 63-69
13. Brodsky, M., B. Allen, C. Walker, T. H. Casey, C. Luckett, W. Hendry: Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Amer. J. Cardiol. 60 (1987), 572-575.
14. Brodsky, M A , B J Allen, E. V. Capparelli, C. R. Luckett, W. L. Henry: Factors determining maintenance of sinus rhythm after chronic atrial fibrillation with left atrial dilatation. Amer J. Cardiol. 63 (1989), 1065-1068.
15. Cameron, A., M. J. Schwartz, R. A. Kronmal, A. S. Kosinski: Prevalence and significance of atrial fibrillation in coronary artery disease (CASS registry) Amer. J. Cardial. 61 (1988), 714-717.
16. Campbell, R. W. F.: Drug prophylaxis of atrial fibrillation. In. Kulbertus, H. E., S. B. Olsson, M. Schlepper (eds.): Atrial fibrillation. Lindgren & Söner AB, Mölndal 1982, p. 274-281.
17. Clementy, J , M. Dulhoste, C Laiter, I. Denjoy, P. Dos Santos: Flecainide acetate in the prevention of paroxysmal atrial fibrillation: a nine-month follow-up of more than 500 patients. Amer. J. Cardiol. 70 (1992), 44A-49A.
18. Coplen, S. E., E. M. Antmann, J. A. Berlin, P. Hewitt, T. C. Chalman: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta analysis of randomized control trials Circulation 82 (1981), 1106-1116.
19. Crijns, H. J., I. C. Van Gelder, W. H. Van Gust, H. Hillege, A. M. Gosselink, K I. Lie: Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or flutter. Amer. J. Cardiol. 68 (1991), 353-341.
20. Ewy, G., L. Ulfers, W D. Hager. Response of atrial fibrillation to therapy: role of etiology and left atrial diameter J Electrocardiol. 12 (1980), 119-124.
21. Fetsch, T, F. Benning, M. Borggrefe, G Breithardt: Atrinal fibrillation Interventional Trial (A-FIT) - Studiendesign und Resultate der ersten Randomisierungs-phase Z. Kardiol. 82 (1992), 139.
22. Frey, W. Über Vorhofflimmern beim Menschen und seine Beseitigung durch Chinidin. Barl. klin. Wschr. 18 (1918), 417-419.
23. Fuchs, T., P. J Podrid: Pharmacologic therapy for reversion of atrial fibrillation and maintenance of sinus rhythm. In Falk, R. H., P. J. Podrid (eds.). Atrial fibrillation Mechanisms and management Raven Press, New York 1992, p. 233-254.
24. Gold, R. L., C. I. Haffajee, G. Charos, K. Sloan, S. Baker, J. S. Alpert. Amiodarone for refractory atrial fibrillation. Amer. J.Cardiol. 57 (1986), 124-127.
25. Gosselink, A. T. M., H. J. G. M. Crijns, I. C. Van Gelder, H. Hillige, A. C. P. Wiesfeld, K. I. Lie: Low dose amiodaron for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. J. Amer med. Ass. 267 (1992), 3289-3293.
26. Gülker, H., H. U. Bramann, B. Brisse, H. Kuhs: Kombinierte Behandlung chronischer Vorhofrhythmusstörungen mit Chinidin/Verapamil Med. Klin. 75 (1980), 196-198
27. Hall, H K., D. R. Wood: Factors affecting cardioversion of atrial arrhythmias with special reference to quinidine, Bnt. Heart J. 30 (1968), 84-88.
28. Hammill, S., D. Wood, B. Gersh, M. Osborn, D. Holmes: Propafenone for paroxysmal atrial fibrillation. Amer. J Cardiol 61 (1988), 473-474.
29. Haverkamp, W , T. Wichter, X. Chen, M. Hördt, S. Willems, B. Rotman, G. Hindricks, H. Kottkamp, M. Borggrefe, G. Breithardt: Proarrhythmische Effekte von Antiarrhythmika Z. Kardiol. 83 (1994), 75-85
30. Haverkamp, W , M. Hördt, X. Chen, G. Hindricks, S. Willems, H. Kottkamp, B. Rotman, J. Brunn: Torsade de pointes, Z. Kardiol. 82 (1993), 763-774.
31. Haverkamp, W., X. Chen, S. Möhlenkamp, A., Lammers, C Hief, G. Hindricks, A. Martinez-Rubio, T. Wtchter, S. Willems, H Kottkamp, B. Rotman, G. Breithardt, M Borggrefe: Akute und chronische Wirksamkeit von Sotalol bei 396 Patienten mit malignen Arrhythmien. Z. Kardiol. 82 (1994), 203.
32. Herre, J M., C Titus, M. Oeff, M Eldar: Inefficacy and proarrhythmic effects of flecainide and ericainide for sustained ventricular tachycardia and fibrillation. Ann. intern. Med. 113 (1990), 671-676.
33. Hindricks, G , H. Kottkamp, S Willems, W Haverkamp, M Borggrefe, G. Breithardt. Medikamentöse Rezidivprophylaxe bei paroxysmalem und chronischem Vorhofflimmern. Z Kardiol. 83 (1994), 87-96.
34. Höglund, G., G. Rosenhamer: Echocardiographic left atrial dimension as a predictor of maintaining sinus rhythm after conversion of atrial fibrillation. Acta med. scand. 217 (1985), 411-415.
35. Hohnloser, S. H., W. Arendts, B. Quart: Torsade de pointes during sotalol therapy. Europ. Heart J. 13 (1992), 305.
36. Hohnloser, S H., M. Zabel: Short- and long-term efficacy of flecainide acetate for supraventricular arrhythmias. Amer. J. Cardiol. 70 (1992), 3-10.
37. Jackman, W M., K. J. Friday, J. L. Anderson, E. M. Aliot, M. Clark, R. Lazzara: The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis Prog cardiovasc. Dis. 31 (1988), 115-172
38. Juul-Möller, S., N. Edvardson, N. Rehnquist-Ahlberg. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 82 (1990), 1932-1939.
39. Kalusche, D., J. Stockinger, P. Betz, H. Roskamm: Sotalol und Chinidin/Verapamil (Cordichin) bei chronischem Vorhofflimmern - Konversion und 12-Monats-Follow-up -ein randomisierter Vergleich. Z. Kardiol. 83 (1994), 109-116.
40. Kannel, W. B., R. D. Abbott, D. D. Savage, M. McNamara: Epidemiologic features of chronic atrial fibrillation; the Framingham study. New Engl. J. Med. 307 (1982), 1018-1022.
41. Kay, G. N., V.J. Plumb, J. G. Arciniegas, R. W. Henthorn, A. L. Waldo: Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J. Amer. Coll. Cardiol. 2 (1983), 806-817.
42. Kehoe, R. F., T. A. Zheutlin, C. S. Dunnington, T. A. Mattioni, G. Yu, R. B. Spangenberg: Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias. Amer. J. Cardiol. 65 (1990), 58-64.
43. Kienast, J., Embolieprophylaxe bei Vorhofflimmern: Antikoagulation und antithrombozytäre Therapie. Z. Kardiol. 83 (1994), 49-58.
44. Kuck, K. H.: Kardioversion. bei Vorhofflimmern. Z. Kardio. 83 (1994), 59-62.
45. Kulbertus, H E.: Atrial fibrillation. Epidemiologic aspects and natural history. In: Kulbertus, H. E., H. J. J. Wellens, I. Bourgeois, R. Sutton (eds.): Atrial fibrillation: Facts from yesterday, ideas for tomorrow. Futura Publishing Company, Armonk NY 1994, p 1-21.
46. Lewis, R. V.: Atrial fibrillation. The therapeutic options. Drugs 40 (1990), 841-853.
47. Lie, K. I., H. J. G. M. Crijns, I. C. Van Gelder: Pharmacological treatment of atrial fibrillation In: Kulbertus, H. E., H J. J. Wellens, I Bourgeois, R. Sutton (eds.): Atrial fibrillation. Facts from yesterday, ideas for tomorrow. Futura Publishing Company, Armonk NY 1994, p. 111-124.
48. Morganroth, J.: Proarrhythmic effects of antiarrhythmic drugs. evolving concepts. Amer. Heart J. 123 (1991), 1137-1139.
49. Petersen, P., J. Godtfredsen: Atrial fibrillation - a review of course and prognosis. Acta med. scand. 216 (1984), 5-9.
50. Podrid, P. J., S. Lampert, T B. Graboys, C. M. Blatt, B. Lown: Aggravation of arrhythmia by antiarrhythmic drugs - incidence and predictors Amer. J. Cardiol. 59 (1987), 38-44.
51. Porterfield, J., L. Porterfield: Therapeutic efficacy and safety of oral propafenone for atrial fibrillation. Amer. J Cardiol. 63 (1989), 114-116
52. Roden, D. M.: The long QT syndrome and Torsade de Pointes: basic and clinical aspects. In: El-Sherif, N., P. Samet P. (eds.): Cardiac pacing and electrophysiology. W. B. Saunders & Co., Philadelphia-London 1991, p. 265-284.
53. Ruskin, J., The cardiac arrhythmia suppression trial (CAST). New Engl. J. Med. 321 (1989), 386-387.
54. Scheffe, H.: The analysis of variance. John Willy & Sons, New York 1959.
55. Scheininger, M., K. Theisen: Therapie des Vorhofflimmerns. Internist (Berl.) 34 (1993), 478-488.
56. Seatle, S. R., G. Casella, C. E. McGulloch: Variance components. John Willy & Sons, New York 1992.
57. Selzer, A.: Atrial fibrillation revisited. New Engl. J.Med 306 (1982), 1044-1045.
58. Selzer, A., H. W. Wray: Quinidine syncope Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythrmas. Circulation 30 (1964), 26-31.
59. Shenasa, M., J. Shenasa, H. Shenasa: Supraventricular arrhythmias Curr. Opin. Cardiol. 6 (1991), 26-34.
60. Soyka, L. F., C. Wirtz, R. B. Spangenberg: Clinical safety profile of sotalol in patients with arrhythmias. Amer. J. Cardiol. 65 (1990), 74-81.
61. Tebbe, U . J. Carlsson, K. H. Seidl, W. Jansen, H. P. Schuster, M Elsner, K. L. Neuhaus, F. Praetonus für die Studiengruppe der Arbeitsgemeinschaft leitender kardiologischer Krankenhausärzte. Med Klin. 90 (1995), 681-687.
62. Trappe, H. J., H. Klein, J. Huang, P. Wenzlaff, P. R. Lichtlen. Comparison of catheter ablation using direct current energy versus radiofrequency: observations in 147 patients with supraventricular tachyarrhythmias. J. intervent. Cardiol. 6 (1993), 137-147.
63. Trappe, H. J.: Anuodaron und Nebenwirkungen. In: Madea, B., U. J. Winter, M. Schwonzen, D. Rademacher (Hrsg.): Innere Medizin und Recht. Konfrontation - Kommunikation - Kooperation. Blackwell Wissenschafts-Verlag, Berlin-Wien 1996, S. 284-296.
64. Van Gelder, I., H Crijns, W. Van Gilst, L. Van Wijk, H. Hamer, K. Lie: Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Amer. J. Cardiol. 64 (1989), 1317-1321.
65. Vitolo, E., M. Tronci, M. T. Larovere: Amiodarone versus quinidine in the prophylaxis of atrial fibrillation Acta cardiol. (Brux.) 36 (1981), 431-437.
66. Wellens, H. J J.: Atrial fibrillation: its consequences. In: Kulbertus, H. E., H. J. J. Wellens, I, Bourgeois, R. Sutton (eds.): Atrial fibrillation: Facts from yesterday, ideas for tomorrow. Futura Publishing Company, Armonk NY 1994, p. 57-71.
67. Zehender, M., T. Meinertz, H. Just: Amiodaron und Verapamil/Chinidin in der Behandlung von Patienten mit chronischern Vorhofflimmern. Z. Kardiol. 83 (1994), 101-108.